<DOC>
	<DOCNO>NCT01040312</DOCNO>
	<brief_summary>The purpose study examine correlation UGT1A1 genotypes safety CPT-11 plus platinum analogue ( cisplatin , carboplatin nedaplatin ) regimens patient lung cancer , cervical cancer , ovarian cancer gastric cancer .</brief_summary>
	<brief_title>An Observational Study CPT-11 Plus Platinum Analogues Regimens UGT1A1 Genotypes Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Small cell lung cancer , nonsmall cell lung cancer , cervical cancer , ovarian cancer gastric cancer Patients UGT1A1 genotype *1/*6 , *1/*28 , *6/*6 , *28/*28 *6/*28 Patients receive CPT11 plus platinum analogue ( cisplatin , carboplatin nedaplatin ) regimens ( without molecular target agent ) Contraindication CPT11 ECOG PS 34</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>UGT1A1 , irinotecan</keyword>
</DOC>